

COMMONWEALTH OF PENNSYLVANIA  
DEPARTMENT OF STATE  
BUREAU OF PROFESSIONAL AND OCCUPATIONAL AFFAIRS

**F I N A L M I N U T E S**

MEETING OF:

**STATE BOARD OF PHARMACY**

TIME: 10:30 A.M.

Held at

**PENNSYLVANIA DEPARTMENT OF STATE**

2525 North 7th Street

CoPA HUB, Eaton Conference Room

Harrisburg, Pennsylvania 17110

as well as

**VIA MICROSOFT TEAMS**

October 7, 2025

State Board of Pharmacy  
October 7, 2025

BOARD MEMBERS:

Christine Roussel, Pharm.D., BCOP, BCSCP, Chairperson  
Arion R. Claggett, Acting Commissioner, Bureau of  
Professional and Occupational Affairs  
Eric Esterbrook, R.Ph., Vice Chairperson  
Janet Getzey Hart, R.Ph., Secretary  
James Reed Jr., R.Ph.  
John R. Slagle, R.Ph.  
Ester Blair, Office of Attorney General

BUREAU PERSONNEL:

Sean C. Barrett, Esquire, Board Counsel  
Shana Walter, Esquire, Deputy Chief Counsel,  
Prosecution Division  
Ashley P. Murphy, Esquire, Board Prosecutor  
Caroline Bailey, Esquire, Board Prosecutor  
Marc Farrell, Esquire, Regulatory Counsel, Office of  
Chief Counsel, Department of State  
Ray J. Michalowski, Esquire, Senior Board Prosecutor  
and Prosecution Liaison  
Sara Trimmer, Pharm.D., R.Ph., Executive Secretary  
Andrew LaFratte, MPA, Deputy Policy Director,  
Department of State  
Willow Marsh, Legislative Aide, Office of Legislative  
Affairs  
Ronald Rouse, Esquire, PA Office of General Counsel  
Jessica Zukoski, Senior Legal Analyst, Department of  
State  
Steven Zahn, Pharmacy Inspector, Bureau of  
Enforcement and Investigation, Department of State  
Miriam Wamsley, Respiratory Virus Epidemiologist,  
Pennsylvania Department of Health

ALSO PRESENT:

Kari Orchard, Executive Director (D), House  
Professional Licensure Committee, Pennsylvania  
House of Representatives  
Jill Rebuck, Executive Director, Pennsylvania Society  
of Health-System Pharmacists  
Susan DelMonico, R.Ph, Associate General Counsel,  
Deputy Pharmacy Compliance Officer, Genoa  
Healthcare

State Board of Pharmacy  
August 26, 2025

ALSO PRESENT: (cont.)

Geoffrey Christ, Senior Compliance Manager, Chewy  
Pharmacy  
Charlotte Harris, Pharmacy Intern, Duquesne  
University  
Jacquelyn Sassaman, Pentec Health  
Misha Patel, M.D., Curriculum Education Assistant,  
Geisinger Commonwealth School of Medicine  
Danielle DiCiolla, Manager, Regulatory Affairs,  
Cardinal Health  
Christopher Miller, Pharm.D., Giant Eagle  
Grace Sesì, Executive Director, Regulatory Affairs,  
CVS Health, Chairperson, Michigan Bureau of  
Pharmacy  
Matthew Schonder, R.Ph., MBA, Director of Pharmacy,  
University of Pittsburgh Medical Center McKeesport  
Anthony Bixler, R.Ph., Staff Pharmacist, Wellspan  
York Hospital  
Victoria Elliott, R.Ph., CEO, Pennsylvania  
Pharmacists Association  
Jon Ference, Pharm.D, Dean, Nesbitt School of  
Pharmacy, Wilkes University  
Heather Wilson, Deputy Executive Vice President,  
Pennsylvania Medical Society, Executive Director,  
Foundation of the Pennsylvania Medical Society  
Joshua Finger, Pharm.D, Enclara Pharmacia  
Daniel Longyhore, Pharm.D., System Director,  
Knowledge Management, Enterprise Pharmacy,  
Geisinger  
Rachel DiPaolantonio, Pharm.D, clinical Program  
Coordinator, Weis Markets  
Lauren Finoli, Manager of Pharmacy Clinical Services,  
Allegheny General Hospital  
Ashley Addison, Pharm.D, Executive Fellow,  
Pennsylvania Pharmacists Association  
Nicole Fidler, Associate, Malady & Wooten  
Frank Konzelman Jr., Pharm.D, BCPS, Pharmacy Manager  
Inpatient, Penn Medicine, University of  
Pennsylvania Health System  
Thomas Turco, Pharm.D, Clinical Staff Pharmacist,  
Penn Medicine, University of Pennsylvania Health  
System  
Tiffany Booher, MA, LPC, CAADC, CIP, CCSM, Director,  
Peer Assistance Monitoring Program, Foundation of  
the Pennsylvania Medical Society

State Board of Pharmacy  
August 26, 2025

ALSO PRESENT: (cont.)

Taylor Schultz, Pharmacy Student, Lake Erie College  
of Osteopathic Medicine  
Ryan Lichtenberg, Pharmacy Compliance Specialist, The  
Giant Company  
Courtney Quattrone, Pharm.D, Patient Care Pharmacist,  
Experiential Coordinator, Albertsons Companies  
Sheetal Kamath, Pharmacist, UPMC Pharmacy  
Kristie Hurd, Pharmacy Scheduler, Giant Eagle  
Steven Bodenbergs, Senior Director, Pharmacy  
Operations, SelectRx  
Heather Sakely, Pharm.D, BCPS, BCGP, Clinical  
Pharmacy Specialist, Geriatric Medicine at UPMC St.  
Margaret  
Tiffany O'Hagan, Vice Chairperson, Wisconsin Board of  
Pharmacy  
Brad Wojciechowski, Executive Director, Wisconsin  
Pharmacy Examining Board  
Rick Seipp, Pharm.D, President, Value Drug Co.  
Timothy Gates, Attorney, Myers, Brier, Kelly LLP  
Simone Sweeney, Pharmacy Student, University of  
Pittsburgh  
Shane Wenner, R.Ph.  
Mayank Amin, Pharm.D, R.Ph, Skipjack Pharmacy  
Destiny Cawley, R.Ph  
Rohail Bilal, R.Ph, Respondent  
Sarah Cronin  
Jessica Cole  
Matt Orme  
Evan Zaharick  
Caroline O  
Logan Martinez  
Paul Martinez  
Marilyn Muse  
Taylor Jones  
Matthew Popowicz  
Scott Young  
Whittney  
Karina  
Call-In 1-570-954-8199  
Call-In 1-856-510-7672  
Call-In 1-267-778-8980  
Erin Badstuebner, Sargent's Court Reporting Service,  
Inc.

\*\*\*

State Board of Pharmacy

October 7, 2025

\*\*\*

The regularly scheduled meeting of the State Board of Pharmacy was held on Tuesday, October 7, 2025. Christine Roussel, Pharm.D., BCOP, BCSCP, Chairperson called the meeting to order at 10:30 a.m.

\*\*\*

[Pursuant to Section 708(a)(5) of the Sunshine Act, at 9:00 a.m., the Board entered into Executive Session with Sean C. Barrett, Esquire, Board Counsel, for the purpose of conducting quasi-judicial deliberations and to receive the advice of Board Counsel. The Board returned to open session at 10:34 a.m.]

\*\*\*

[Sean C. Barrett, Esquire, Board Counsel, noted the the meeting was being recorded, and those who continued to participate were giving their consent to be recorded.

Mr. Barrett also noted the Board entered into Executive Session for the purpose of conducting quasi-judicial deliberations on a number of matters that are currently pending before the Board and to

1 receive the advice of counsel.]

2 \*\*\*

3 Introduction of Board Members/Attendees

4 [Christine Roussel, Pharm.D., BCOP, BCSCP,  
5 Chairperson, requested an introduction of Board  
6 members and attendees.]

7 \*\*\*

8 Approval of the Minutes

9 CHAIR ROUSSEL:

10 We had two sets of meeting minutes.  
11 We've been busy, so I guess we can ask  
12 for the August 26, 2025. Did anybody  
13 have any amendments or edits? Any  
14 issues with the meeting minutes from  
15 the special meeting for September 3,  
16 2025?

17 So with that, may I move to make a  
18 motion for us to approve both meeting  
19 minutes from August and September at  
20 the same time?

21 MR. ESTERBROOK:

22 I'll make the motion to approve the  
23 minutes, Esterbrook.

24 MR. REED:

25 Reed, second.

1 CHAIR ROUSSEL:

2 Okay, so let's call the vote.

3

4 Reed, aye; Slagle, aye; Hart, aye;

5 Esterbrook, aye; Claggett, aye; Blair,

6 aye; Roussel, aye.

7 [The motion carried unanimously.]

8 \*\*\*

9 Report of Board Prosecution

10 [Caroline Bailey, Esquire, Board Prosecutor,

11 presented the Consent Agreements for Agenda Item No.

12 6, Case No. 25-54-004421; and Agenda Item No. 7, Case

13 No. 23-54-014942.]

14 \*\*\*

15 [Ray J. Michalowski, Esquire, Senior Board Prosecutor  
16 and Prosecution Liaison, on behalf of Nathan C.

17 Giunta, Esquire, Board Prosecution Liaison, presented

18 the Consent Agreements for Agenda Item No. 8, Case

19 Nos. 24-54-015788 and 24-54-015790; Agenda Item No.

20 9, Case No. 24-54-016034; Agenda Item No. 10, Case

21 No. 25-54-002024; and Agenda Item No. 11, Case No.

22 25-54-003777.]

23 \*\*\*

24 [Ray J. Michalowski, Esquire, Senior Board Prosecutor  
25 and Prosecution Liaison, presented the VRP Consent

1 Agreement for Agenda Item No. 12, Case No. 25-54-  
2 010676.]

3 \*\*\*

4 MR. BARRETT:

5 Based on the presentation of  
6 Prosecution, does any member of the  
7 Board wish to reenter Executive Session  
8 for further deliberations?

9 Hearing none, based on the  
10 presentation of Prosecution and  
11 Executive Session deliberations, I  
12 believe the Board Chair would entertain  
13 a motion to approve the Consent  
14 Agreements at Item No. 6, Case No. 25-  
15 54-004421; Item No. 7, Case No. 23-54-  
16 014942; Item No. 8, Case Nos. 24-54-  
17 015788 and 24-54-015790; Item No. 9,  
18 Case No. 24-54-016034; and Item No. 12,  
19 Case No. 25-54-010676.

20 MR. ESTERBROOK:

21 So moved, Esterbrook.

22 MR. REED:

23 Reed, second.

24 CHAIR ROUSSEL:

25 Any further discussion? Seeing none,



1                   let's call the vote.

2

3                   Reed, aye; Slagle, aye; Hart, aye;  
4                   Esterbrook, aye; Claggett, aye; Blair,  
5                   aye; Roussel, aye.

6 [The motion carried unanimously. The Respondents'  
7 names are as follows: Agenda Item No. 6, Case No.  
8 25-54-004421, Richard Todd Miller, R.Ph; Agenda Item  
9 No. 7, Case No. 23-54-014942, Optum Infusion Services  
10 500 Inc; Agenda Item No. 8, Case Nos. 24-54-015788  
11 and 24-54-015790, Ahmed Moftah, R.Ph, and Universal  
12 RX a/k/a Penn Specialty Pharmacy; and Agenda Item No.  
13 9, Case No. 24-54-016034, Rohail A. Bilal, R.Ph.]

14

\*\*\*

15 MR. BARRETT:

16                   At Item No. 10, I'll note for the  
17                   record, Board Member Hart did recuse  
18                   from any Executive Session  
19                   deliberations in this matter.

20                   Based on Executive Session  
21                   deliberations and presentation of  
22                   Prosecution, I believe the Board Chair  
23                   would entertain a motion to approve the  
24                   Consent Agreement at Case No. 25-54-  
25                   002024.

1 MR. ESTERBROOK:

2 So moved, Esterbrook.

3 MR. REED:

4 Reed, second.

5 CHAIR ROUSSEL:

6 Any further discussion? Hearing none.

7 We'll call the vote.

8

9 Reed, aye; Slagle, aye; Hart, recuse;

10 Esterbrook, aye; Claggett, aye; Blair,

11 nay; Roussel, aye.

12 [The motion carried. Janet Getzey Hart recused

13 herself from deliberations and voting on the matter.

14 The Respondent's name at Agenda Item No. 10, Case No.

15 25-54-002024 is Joseph W. Snyder, RPh.

16 \*\*\*

17 MR. BARRETT:

18 At Item No. 11, I'll note for the

19 record that Board Member Reed did

20 recuse himself from any Executive

21 Session deliberation or participation

22 in this matter.

23 Based on Executive Session

24 Deliberations and Report of Board

25 Prosecution, I believe the Board Chair

1 would entertain a motion to approve the  
2 Consent Agreement at Item No. 11, Case  
3 No. 25-54-003777.

4 MR. ESTERBROOK:

5 So moved, Esterbrook.

6 ACTING COMMISSIONER CLAGGETT:

7 Claggett, second.

8 CHAIR ROUSSEL:

9 Any discussion? Okay, let's call the  
10 vote.

11

12 Reed, recuse; Slagle, aye; Hart, aye;  
13 Esterbrook, aye; Claggett, aye; Blair,  
14 aye; Roussel, aye.

15 [The motion carried. James Reed recused himself from  
16 deliberations and voting on the matter. The  
17 Respondent at Item No. 11, Case No. 25-54-003777 is  
18 Walgreens Specialty Pharmacy #16070.]

19

\*\*\*

20 Appointment - Introduction - Deputy Chief Counsel,  
21 Shana Walter

22 [Shana Walter, Esquire, Deputy Chief Counsel,  
23 Prosecution Division, introduced herself to the  
24 Board. She noted observing the Pharmacy Board  
25 meetings for the last couple of months to familiarize

1 herself with the Board. She shared a brief summary  
2 of her background including a volunteer job as a  
3 child. She offered to be available for questions  
4 from the Board.]

5 \*\*\*

6 Appointment - Early MPJE Program - Wisconsin Board of  
7 Pharmacy

8 [Tiffany O'Hagan, Vice Chairperson, Wisconsin Board  
9 of Pharmacy, presented the Board with a slideshow  
10 regarding the early MPJE pilot program Wisconsin is  
11 participating in with North Dakota. Ms. O'Hagan  
12 provided the Board with a background of the pilot  
13 program with Wisconsin. Wisconsin has three schools  
14 participating, and this is the second full year  
15 students have been allowed to take the MPJE as soon  
16 as their didactic learning is complete.

17 Ms. O'Hagan noted the feedback has been largely  
18 positive of the program. Students report feeling  
19 less overwhelmed by separating the NAPLEX and MPJE  
20 exams. In addition, exam sites are not overwhelmed  
21 with students. Students are also able to be licensed  
22 quicker as the only post-graduation exam is the  
23 NAPLEX. She also reported, in the second year of the  
24 program, almost full participation from eligible  
25 students.

1 Ms. O'Hagan reviewed the pilot workflow for the  
2 Board. She noted, if a student needs to make a  
3 second attempt at the MPJE, there is a manual process  
4 to return to an unverified status due to it being a  
5 pilot program. NABP is considering expanding the  
6 process and making it more automated but are working  
7 to ensure there are no gaps where students can apply  
8 for an exam they are not yet eligible. In addition,  
9 if a second attempt is needed, the student has to  
10 wait until after graduation.

11 Ms. O'Hagan noted, in Wisconsin, 96 percent of  
12 students applied, and 126 students were granted  
13 eligibility. Wisconsin noticed a shorter time frame  
14 from registration to purchasing the examination with  
15 the biggest spike of taking the exam in September.  
16 The pilot passing rate was 74 percent, down from an  
17 average of 80.5 percent, however Ms. O'Hagan stated  
18 the rate has risen in the second year. She provided  
19 the Board with a slide showing the passing curve.

20 Chair Roussel asked if there were any regulatory  
21 changes needed in Wisconsin to use the pilot program.

22 Ms. O'Hagan reported Wisconsin regulations were  
23 written in a way where regulatory changes were not  
24 needed. Wisconsin regulations state the law exam  
25 must be taken but do not specify when the exam is to

1 be taken.

2 Anthony Bixler, R.Ph., Staff Pharmacist, Wellspan  
3 York Hospital, asked if there was a commonality  
4 between students who were not granted eligibility to  
5 test. Ms. O'Hagan did not have that information from  
6 NABP, but it could be investigated.

7 Chair Roussel and Ms. Trimmer discussed the  
8 number of pharmacy students who graduate in  
9 Pennsylvania each year. Ms. Trimmer noted students  
10 may graduate in Pennsylvania but go to other states  
11 for licensure.

12 Ms. O'Hagan noted students from the 2024  
13 graduating class were the first to be eligible to  
14 take the MPJE in late 2023. She added it would be  
15 too early to determine if there was any increase in  
16 disciplinary actions. She also noted schools have  
17 reported early examination has helped students  
18 prepare and be more alert of rules and regulations  
19 while in clinical rotation.

20 Mr. Barrett asked if there has been an increase  
21 in passing the NAPLEX due to potentially having more  
22 time to prepare between exams. Ms. O'Hagan stated  
23 she had not seen any data but would check with NABP.

24 Chair Roussel asked for confirmation the process  
25 for students is a bit more streamlined for NAPLEX

1 registration as NABP registration is completed  
2 earlier. Ms. O'Hagan confirmed she was correct.  
3 When asked, Ms. O'Hagan also confirmed transcripts go  
4 to NABP to verify exam eligibility and not through  
5 the state boards.

6 Mr. Barrett asked what would happen if a student  
7 passed the MPJE early but then did not graduate for  
8 some reason. He wondered if the student would have  
9 to retake the MPJE if they eventually graduated. Ms.  
10 O'Hagan stated the scenario had not happened yet so  
11 she did not have an answer.

12 Chair Roussel thanked Ms. O'Hagan for her time  
13 and for sharing the insights regarding the pilot  
14 program.]

15 \*\*\*

16 Report of Board Counsel - Final Adjudication and  
17 Order

18 MR. BARRETT:

19 Based on Executive Session  
20 deliberations, I believe the Board  
21 Chair would entertain a motion to  
22 approve the Final Adjudication and  
23 Order at Item No. 16, Case No. 20-54-  
24 011597, Keesha Dinkins Jones, R.Ph.

25 MR. ESTERBROOK:

1                   So moved, Esterbrook.

2 MR. REED:

3                   Reed, second.

4 CHAIR ROUSSEL:

5                   Any discussion?   Hearing none.   Let's  
6                   call the vote.

7

8                   Reed, aye; Slagle, aye; Hart, aye;  
9                   Esterbrook, aye; Claggett, aye; Blair,  
10                  aye; Roussel, aye.

11 [The motion carried unanimously.]

12                                   \*\*\*

13 Review of Applications

14 MR. BARRETT:

15                   Based on Executive Session  
16                   Deliberations, I believe the Board  
17                   Chair would entertain a motion to  
18                   provisionally deny the Application for  
19                   Pharmacist by Exam of Robert Kisiel.

20 MR. ESTERBROOK:

21                   So moved, Esterbrook.

22 MR. REED:

23                   Reed, second.

24 CHAIR ROUSSEL:

25                   Any discussion?   Let's call the vote.



1

2

Reed, aye; Slagle, aye; Hart, aye;

3

Esterbrook, aye; Claggett, aye; Blair,

4

aye; Roussel, aye.

5

[The motion carried unanimously.]

6

\*\*\*

7

MR. BARRETT:

8

Based on Executive Session

9

Deliberations, I believe the Board

10

Chair would entertain a motion to

11

approve the Applications of Sahr

12

Gbakima, Emma Brooks, and BB Myrtle for

13

their respective Applications.

14

MR. ESTERBROOK:

15

So moved, Esterbrook.

16

MR. REED:

17

Reed, second.

18

CHAIR ROUSSEL:

19

Any discussion? Hearing none. Let's

20

call the vote.

21

22

Reed, aye; Slagle, aye; Hart, aye;

23

Esterbrook, aye; Claggett, aye; Blair,

24

aye; Roussel, aye.

25

[The motion carried unanimously.]

\*\*\*

MR. BARRETT:

Based on Executive Session  
Deliberations, I believe the Board  
Chair would entertain a motion to  
provisionally deny the Non-Resident  
Pharmacy Application of HRx.

MR. ESTERBROOK:

So moved, Esterbrook.

MR. REED:

Reed, second.

CHAIR ROUSSEL:

Any discussion? Let's call the vote.

Reed, aye; Slagle, aye; Hart, aye;  
Esterbrook, aye; Claggett, aye; Blair,  
aye; Roussel, aye.

[The motion carried unanimously.]

\*\*\*

Report of Board Counsel - PA Support Curriculum

[Sean C. Barrett, Esquire, Board Counsel, stated the  
PA Support Curriculum is a curriculum contracted by  
the Department of Education with Temple University  
for the opioid continuing education (CE). Mr.  
Barrett was currently working on the Pharmacy Board's

1 opioid CE regulation and plans to have the draft  
2 annex at the November meeting. He stated all of the  
3 other relevant Boards have adopted the PA Support  
4 Curriculum. He added the curriculum is not mandatory  
5 in that it would not be required for providers to  
6 issue it. The curriculum, if offered by a provider,  
7 would be Board approved.

8 Chair Roussel stated the curriculum was well-  
9 written. However, she expressed disappointment no  
10 pharmacist was involved in creating an educational  
11 document about understanding pain, prescribing  
12 opioids and recovery treatment.]

13 \*\*\*

14 MR. BARRETT:

15 Based on our discussion here in open  
16 session, I believe the Board Chair  
17 would entertain a motion to approve the  
18 PA Support Curriculum to satisfy the  
19 two-hour opioid CE requirement of the  
20 Board.

21 MR. ESTERBROOK:

22 So moved, Esterbrook.

23 MR. REED:

24 Reed, second.

25 CHAIR ROUSSEL:

1 Any discussion? Hearing none. Let's  
2 call the vote.

3  
4 Reed, aye; Slagle, aye; Hart, aye;  
5 Esterbrook, aye; Claggett, aye; Blair,  
6 aye; Roussel, aye.

7 [The motion carried unanimously.]

8 \*\*\*

9 Report of Board Counsel - Regulatory Report

10 [Marc Farrell, Esquire, Regulatory Counsel, Office of  
11 Chief Counsel, Department of State, reported the  
12 Board currently has five open regulations.

13 General Revisions, 16A-5427, is in the proposed  
14 stage. Mr. Farrell stated his office is drafting the  
15 remainder of the package and hoped to send it to the  
16 Governor's Office for review by the end of the year.  
17 Mr. Barrett noted the Board sees the Annex and  
18 Preamble but does not see the additional Regulatory  
19 Analysis Form, which covers justifications for  
20 changes and legalities. He added the form is 28 or  
21 32 questions and varies based on the complexity and  
22 scope of the regulation package.

23 Child Abuse Reporting Requirements, 16A-5430, is  
24 in the final rulemaking stage. Mr. Farrell reported,  
25 since the last meeting, the package had been approved

1 by the Governor's Office and delivered to IRRC and  
2 the Legislative Standing Committees. He noted the  
3 package is on IRRC's meeting agenda for October 16,  
4 2025. He added the package is deemed approved and  
5 will likely be completed by the next Board meeting.

6 Licensure by Endorsement (Act 41), 16A-5432, is  
7 currently with the Governor's Office and is expected  
8 back soon. Mr. Farrell explained the next step will  
9 be the Attorney General's Office for review before  
10 proceeding to IRRC and being published as proposed.

11 COVID-19 or Immunization Updates, 16A-5434, is  
12 being executed as final omitted. The regulation will  
13 bring the regulations into alignment with Act 80 of  
14 2022 and Act 77 of 2024. The final omitted process  
15 eliminates some of the regular steps in the  
16 regulation process. He added the final regulation  
17 might be published by the end of the year or shortly  
18 thereafter.

19 Mr. Barrett reported the last regulation, 16A-  
20 5435 regarding the ABC-MAP Opioid Education, will be  
21 presented soon to the Board as a draft Annex.]

22 \*\*\*

23 Discussion - Executive Order 2025-02

24 [Sean C. Barrett, Esquire, Board Counsel, introduced  
25 Executive Order 2025-02, signed by Governor Shapiro

1 on October 1, 2025. The Executive Order, *Protecting*  
2 *Pennsylvanians' Health and Freedom by Ensuring Access*  
3 *to Safe and Effective Vaccines*, reaffirms  
4 Pennsylvania's commitment to evidence-based vaccine  
5 guidance and keeping vaccines accessible and  
6 affordable for all residents of the Commonwealth.  
7 The order is in response to recent federal changes to  
8 vaccine policy, which have created uncertainty around  
9 national vaccine recommendations.

10 Mr. Barrett explained, under the Executive Order,  
11 the Department of Health will develop a state-based  
12 program to ensure children continue to receive  
13 recommended vaccines even if federal coverage  
14 changes; create a central public website with  
15 accurate evidence-based vaccine information; and  
16 convene a vaccine education workgroup that will  
17 include state agencies, health professionals and  
18 community representatives to advise on vaccine access  
19 and education.

20 Mr. Barrett noted the Board of Pharmacy had  
21 already acted to be ahead of the Executive Order by  
22 preapproving other competent authorities. He added  
23 the Boards of Medicine, Osteopathic Medicine, and  
24 Nursing were considering possibilities to help  
25 implement the Executive Order, but no immediate

1 action is required by the Board of Pharmacy.  
2 Agencies such as the Insurance Department, Department  
3 of Human Services, and Department of Aging have been  
4 directed to ensure vaccines remain covered and  
5 accessible for all populations, including Medicaid  
6 recipients and older adults.

7 Mr. Barrett noted the order serves to reinforce  
8 the importance of the Board's continues collaboration  
9 with the Department of Health and the Board's role in  
10 supporting clear, evidence-based vaccine information  
11 for licensees and the public.

12 Chair Roussel expressed appreciation for the  
13 order and for Governor Shapiro.]

14 \*\*\*

15 Discussion - Pharmacy Technician Registration  
16 [Christine Roussel, Pharm.D., BCOP, BCSCP,  
17 Chairperson, asked for an update on the progress of  
18 the pharmacy technician registrations and insights  
19 from Ms. Trimmer.

20 Ms. Trimmer noted the office is receiving an  
21 average of ten applications a day. She shared adding  
22 a snapshot of requirements to the website has not  
23 been forgotten and will be posted once approved.

24 She stated one of the biggest issues is, if a  
25 person fails to put their high school education in

1 when starting the application, their diploma or  
2 transcript has to be sent into the office.

3 Ms. Trimmer also noted applicants are given a  
4 specific code for IdentoGo, which must be provided  
5 for Ms. Trimmer to access their information,  
6 including the FBI background check.

7 Chair Roussel had received complaints stating the  
8 Board will not accept fingerprinting done by their  
9 employer. She stated, for the Board to have access  
10 to a person's fingerprinting, the access has to be  
11 granted at the time of the fingerprinting. She  
12 stressed the importance of the codes used by  
13 IdentoGo.

14 Chair Roussel also stated Ms. Trimmer had  
15 thoughtfully worked on FAQs for the website. Chair  
16 Roussel explained the FAQs have to go through an  
17 approval process before they can be posted on the  
18 website.

19 Mr. Bixler asked for clarification surrounding  
20 the self-query. He added technicians have half an  
21 hour to download the file needed for submission to  
22 PALS. He had a couple of technicians print and  
23 submit to PALS the face sheet from the data bank  
24 showing the number of inquiries. Ms. Trimmer stated  
25 she needed the actual file that was sent to the



1 applicant. She noted the applicant can take a  
2 picture and send that in. She has to be able to  
3 verify the information matches what is in the system,  
4 there are no data bank reports, and it is within six  
5 months.

6 Mr. Barrett noted a recent House Bill being  
7 worked on will hopefully help grandfather some people  
8 into the workforce as registered pharmacy  
9 technicians. Jill Rebuck, Executive Director,  
10 Pennsylvania Society of Health-System Pharmacists,  
11 asked if there was an estimated timeframe for when  
12 the FAQs would be posted on the website. Mr. Barrett  
13 hoped it would be in the next couple of weeks.

14 Mr. Bixler noted several technicians have gone  
15 through the registration process with no issues.

16 Ms. Rebuck reported PSHP drafted their own FAQs  
17 after receiving some clarifications from the Board.  
18 She noted a recent question required an attorney as  
19 it was related to her record. The person was advised  
20 to go through the process, and the Board would  
21 determine their eligibility for registration.

22 Mr. Barrett explained pharmacy technicians'  
23 applications use the same Act 53 determination for  
24 offenses that applies to pharmacists in terms of  
25 criminal history.]

\*\*\*

Report of Board Counsel

[Sean C. Barrett, Esquire, Board Counsel, asked if the temporary provisional endorsement license applications had decreased and how many had been issued.

Ms. Trimmer noted, as of the prior week, 101 licenses were issued. A couple additional applications had come in over the prior week.

Mr. Barrett stated the temporary provisional endorsement license seemed to be successful. He hoped it made a difference to pharmacists in the field and noted the licenses expire January 2, 2026.]

\*\*\*

Report of Board Chairperson

[Christine Roussel, Pharm.D., BCOP, BCSCP, Chairperson, reminded everyone Pennsylvania would be hosting the NABP District 1 and District 2 for the annual meeting in Philadelphia, October 15-17, 2025. She provided a brief summary of the schedule for the meeting, including a number of speakers, highlighting innovative practices, and state regulations.

Chair Roussel reported on traveling to Chicago with Ms. Hart in September 2025 to work with NABP on MPJE questions. The pool of MPJE questions,

1 approximately 3,500 questions, is reviewed yearly by  
2 board of pharmacy members. The questions reviewed  
3 include scored questions that are actionable for  
4 current tests as well as new questions.]

5 \*\*\*

6 Report of Board Members - No Report

7 \*\*\*

8 Report of Acting Commissioner - No Report

9 \*\*\*

10 Report of Executive Secretary - No Report

11 \*\*\*

12 Public Comment

13 [Victoria Elliott, R.Ph., CEO, Pennsylvania  
14 Pharmacists Association, asked if the PA Support  
15 Curriculum was ACP accredited.

16 Mr. Barrett replied it was not accredited. He  
17 noted, in the scheme of the opioid education  
18 regulation, the requirement will be the CE is from an  
19 accredited program, but the Board will still allow  
20 the PA Support Curriculum if offered.

21 Ms. Elliott stated pharmacists might be more  
22 motivated to use the curriculum if it was accredited.

23 Mr. Barrett noted discussion could be had on how  
24 it would be accredited and how it would count towards  
25 the 30 CE hours.

1           Chair Roussel stated the curriculum is through  
2 the Katz School of Medicine at Temple University and  
3 perhaps talking to a pharmacist at university might  
4 be a good idea.

5           Ms. Elliott asked if the child abuse regulation  
6 would change any of the requirements. Mr. Barrett  
7 noted everything should remain the same as the  
8 regulation is intended to run the same way as  
9 everything under the Act.

10          Ms. Elliot questioned the impetus was for the  
11 opioid regulations and what the expectations would  
12 be. Mr. Barrett stated the Act has been passed  
13 several years ago to require the opioid education.  
14 The regulation is taking the Act and turning into the  
15 regulations. The regulation is updating the CE  
16 requirements to reflect opioid education as a  
17 requirement.

18          Ms. Elliott stated PPA reached out to the  
19 Governor's Office since the Executive Order and  
20 thanked them for bringing clarification to vaccine  
21 guidance. She noted there is still some confusion  
22 surrounding vaccines and eligibility.

23          Mr. Barrett acknowledged there is uncertainty  
24 surrounding vaccines as different pharmacies are  
25 doing different things depending on what their

1 physicians will authorize. He noted the Board will  
2 do what it can to allow vaccine access, but the Board  
3 cannot control what policies pharmacies have.

4 Chair Roussel received similar concerns regarding  
5 vaccines. She noted every pharmacy, especially  
6 independent pharmacies, have the right to choose to  
7 practice and do what they feel comfortable with based  
8 on their own scope.]

9 \*\*\*

10 Report of Board Counsel - Discussion regarding

11 Jurisprudence Examination Requirement

12 [Christine Roussel, Pharm.D., BCOP, BCSCP,  
13 Chairperson, explained one of the items removed from  
14 the General Regulations package was how the Board  
15 wanted to move forward with the law exam. She  
16 reviewed possible options, including keeping the  
17 current MPJE after graduation, changing to the UMPJE,  
18 allowing students to take the law exam before  
19 graduation or removing the law exam requirement  
20 entirely. Chair Roussel noted the MPJE is state  
21 specific while the UMPJE would be a universal exam  
22 from NABP.

23 Mr. Barrett reported, according to the NABP  
24 website, 45 boards require the passing of the MPJE.  
25 Four boards, Arkansas, California, Nevada and Puerto

1 Rico have their own jurisprudence exam. Five boards,  
2 Alaska, Idaho, Michigan, Vermont and the Virgin  
3 Islands have eliminated the jurisprudence exam. He  
4 suggested the Board invite one or more boards for  
5 insights if it wants to consider eliminating the  
6 exam.

7 Mr. Reed asked if the UMPJE as a universal test  
8 would also have state-specific modules similar to CE  
9 requirement. Chair Roussel there was an option with  
10 the UMPJE to require state-specific modules. Another  
11 option with no UMPJE would be just a required state-  
12 specific process like a Pennsylvania law review CE  
13 with follow-up questions. She noted the process  
14 would be similar to what is required for child abuse  
15 CE in Pennsylvania. She also stated the logistics  
16 between doing both the UMPJE and the Pennsylvania  
17 module might be cumbersome. However, she added a  
18 Pennsylvania specific module might be useful for new  
19 pharmacists coming from other states. She noted the  
20 Board has the purview to contract with someone to  
21 create a state-specific module.

22 Ms. Rebuck stated PSHP would likely be supportive  
23 of a state-specific CE module. She reiterated PSHP's  
24 opposition to requiring any pharmacy jurisprudence  
25 exam which is consistent with the American Society of

1 Health-System Pharmacists. She added Governor  
2 Shapiro has made addressing healthcare worker  
3 shortages a priority and has generally spoken about a  
4 desire to ease the process for medical professionals.

5 Chair Roussel posed the question if the  
6 pharmacists recently issued temporary licenses to  
7 practice in Pennsylvania had any discipline acted  
8 against them.

9 Mr. Barrett stated the licenses were only three  
10 months old and investigations into conduct take time,  
11 so he has not heard of any issues. He added, under  
12 Act 41, the MPJE is not required due to the caveat of  
13 the applicant having been a practicing pharmacist in  
14 their state for two of the last five years. He would  
15 not use a lack of discipline for temporary licensees  
16 as an impetus to eliminate the exam.

17 Chair Roussel noted NABP would be providing an  
18 update on the UMPJE at the Philadelphia meeting. She  
19 added the current intention is for the exam to be  
20 ready for 2026 or 2027.

21 Mr. Farrell noted his office has tried to advance  
22 the regulation changes for the UMPJE by adjusting the  
23 regulation to read "or other pharmacy jurisprudence  
24 examination" instead of just "the multi-state  
25 jurisprudence exam."

1       Chair Roussel stated, with the wording added to  
2 the regulation, the discussion should be on allowing  
3 early testing or in lieu of a test, doing an  
4 education CE type program.

5       Mr. Barrett found it interesting to hear the  
6 perspective of Wisconsin. He would like to know if  
7 separating the jurisprudence from the NAPLEX leads to  
8 a higher pass rate on NAPLEX. He suggested it would  
9 be beneficial to do early testing.

10       Chair Roussel will extend invitations to states  
11 who have eliminated the exam to the next Board  
12 meeting.

13       Daniel Longyhore, Pharm.D., System Director,  
14 Knowledge Management, Enterprise Pharmacy, Geisinger,  
15 stated a cursory review showed Idaho enacted their  
16 legislation in 2018 and Michigan in 2023, so Idaho  
17 would have more experience to speak on.

18       Ms. Rebuck added PSHP is working on polling their  
19 membership with questions around the jurisprudence  
20 exam. She asked the Board to be thoughtful if adding  
21 a Pennsylvania CE modal on top of the exam as it  
22 could delay licensure to add another barrier.

23       Chair Roussel noted the CE would be lieu of an  
24 exam. The CE would likely be available online, 24  
25 hours a day and people would receive a certificate



1 similar to child abuse. She wondered if PSHP might  
2 gain better information if they polled people who had  
3 taken the exam and gained licensure within the last  
4 two to three years as opposed to someone who took it  
5 30 years ago. She noted the Board would be  
6 interested in hearing what newer graduates say  
7 regarding the applicability of the studying and  
8 testing process related to the value of the exam.

9 Chair Roussel noted AACP requires schools to have  
10 law in their curriculum, and schools would not be  
11 able to remove law from the curriculum if the Board  
12 eliminated the jurisprudence exam requirement. She  
13 added schools have reported being able to better  
14 support students when they take the exam early,  
15 especially if the student fails the exam.]

16 \*\*\*

17 [The Board held a brief recess from 12:02 p.m. until  
18 12:07 p.m.]

19 \*\*\*

20 [A Formal Hearing was held from 12:07 p.m. until  
21 12:59 p.m. in the Matter of Shane Christopher Wenner,  
22 Case No. 25-54-011886.]

23 \*\*\*

24 [Arion R. Claggett, Acting Commissioner, Bureau of  
25 Professional and Occupational Affairs, exited the

1 meeting at 12:38 p.m.]

2 \*\*\*

3 [Pursuant to Section 708(a)(5) of the Sunshine Act,  
4 at 12:59 p.m., the Board entered into Executive  
5 Session with Sean C. Barrett, Esquire, Board Counsel,  
6 for the purpose of conducting quasi-judicial  
7 deliberations and to receive the advice of Board  
8 Counsel. The Board returned to open session at 1:07  
9 p.m.]

10 \*\*\*

11 MR. BARRETT:

12 Based on Executive Session  
13 deliberations and the Presentation of  
14 the Commonwealth and the Petitioner, in  
15 the matter of Shane Christopher Wenner,  
16 Case No. 25-54-011886, I believe the  
17 Board Chair would entertain a motion to  
18 direct Counsel to draft an Adjudication  
19 and Order consistent with Executive  
20 Session Deliberations.

21 MR. ESTERBROOK:

22 So moved, Esterbrook.

23 MR. REED:

24 Reed, second.

25 CHAIR ROUSSEL:

1 Any discussion? Hearing none. Let's  
2 call the vote.

3  
4 Reed, aye; Slagle, aye; Hart, aye;  
5 Esterbrook, aye; Blair, aye; Roussel,  
6 aye.

7 [The motion carried unanimously.]

8 \*\*\*

9 Adjournment

10 CHAIR ROUSSEL:

11 All right, so with that, I believe  
12 we've conducted all our business.

13 Does anybody want to make a motion  
14 to end the meeting?

15 MR. ESTERBROOK:

16 Motion to close.

17 MR. SLAGLE:

18 I'll second that.

19 CHAIR ROUSSEL:

20 All in favor? Let's consider the  
21 meeting adjourned.

22 \*\*\*

23 [There being no further business, the State Board of  
24 Pharmacy Meeting adjourned at 1:08 p.m.]

25 \*\*\*

## CERTIFICATE

I hereby certify that the foregoing summary minutes of the State Board of Pharmacy meeting, was reduced to writing by me or under my supervision and the minutes accurately summarize the substance of the State Board of Pharmacy meeting.



Rachel Wilbur,

Minute Clerk

Sargent's Court Reporting  
Service, Inc.

STATE BOARD OF PHARMACY  
REFERENCE INDEX

October 7, 2025

TIME	AGENDA
9:00	Executive Session
10:30	Return to Open Session
10:30	Official Call to Order
10:31	Introduction of Board Members/Attendees
10:34	Approval of Minutes
10:36	Report of Prosecution
10:50	Appointment - Shana Walter
10:53	Appointment - Wisconsin Board of Pharmacy
11:07	Report of Board Counsel
11:08	Review of Applications
11:11	Regulatory Report
11:19	Discussion
11:31	Report of Board Chairperson
11:36	Public Questions
12:02	Recess
12:07	Appointment - Hearing
12:59	Executive Session
1:07	Return to Open Session
1:07	Motion on Hearing
1:08	Adjournment